510 related articles for article (PubMed ID: 27476742)
41. Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression.
Dell'Acqua R; Galli L; Poli A; Mastrangelo A; Guffanti M; Tadini P; Zandona D; Danise A; Gianotti N; Lazzarin A; Castagna A; Nozza S
AIDS; 2019 Nov; 33(13):1987-1994. PubMed ID: 31306174
[TBL] [Abstract][Full Text] [Related]
42. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
[TBL] [Abstract][Full Text] [Related]
43. SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Achieng B; Sepeka M; Tlali K; Sao L; Thin K; Klimkait T; Battegay M; Labhardt ND
BMC Infect Dis; 2018 Feb; 18(1):76. PubMed ID: 29433430
[TBL] [Abstract][Full Text] [Related]
44. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure.
Mira JA; Macías J; Nogales C; Fernández-Rivera J; García-García JA; Ramos A; Pineda JA
Antivir Ther; 2002 Dec; 7(4):251-6. PubMed ID: 12553479
[TBL] [Abstract][Full Text] [Related]
45. Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
[TBL] [Abstract][Full Text] [Related]
46. Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.
Wirden M; Todesco E; Valantin MA; Lambert-Niclot S; Simon A; Calin R; Tubiana R; Peytavin G; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2015 Aug; 70(8):2347-53. PubMed ID: 25921516
[TBL] [Abstract][Full Text] [Related]
47. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
Elvstam O; Medstrand P; Yilmaz A; Isberg PE; Gisslén M; Björkman P
PLoS One; 2017; 12(7):e0180761. PubMed ID: 28683128
[TBL] [Abstract][Full Text] [Related]
48. Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.
McKinnon E; Castley A; Payne L; Pummer S; Nolan D
HIV Med; 2016 Aug; 17(7):495-504. PubMed ID: 26537660
[TBL] [Abstract][Full Text] [Related]
49. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
[TBL] [Abstract][Full Text] [Related]
50. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.
Hofstra LM; Mudrikova T; Stam AJ; Otto S; Tesselaar K; Nijhuis M; Wensing AM
PLoS One; 2014; 9(10):e110749. PubMed ID: 25354368
[TBL] [Abstract][Full Text] [Related]
51. Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
Lee KJ; Shingadia D; Pillay D; Walker AS; Riordan A; Menson E; Duong T; Tudor-Williams G; Gibb DM;
Antivir Ther; 2007; 12(6):949-56. PubMed ID: 17926649
[TBL] [Abstract][Full Text] [Related]
52. Antiretroviral treatment failure predicts mortality in rural Tanzania.
Pettersen PS; Brox IK; Naman E; Bruun JN; Dyrhol-Riise AM; Trøseid M; Johannessen A
Int J STD AIDS; 2015 Aug; 26(9):633-9. PubMed ID: 25122578
[TBL] [Abstract][Full Text] [Related]
53. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.
Zheng L; Bosch RJ; Chan ES; Read S; Kearney M; Margolis DM; Mellors JW; Eron JJ; Gandhi RT;
Antivir Ther; 2013; 18(1):39-43. PubMed ID: 22914318
[TBL] [Abstract][Full Text] [Related]
54. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
Poveda E; Crespo M
AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
[TBL] [Abstract][Full Text] [Related]
55. Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy.
Charuratananon S; Sungkanuparph S
J Int Assoc Provid AIDS Care; 2015; 14(1):12-6. PubMed ID: 24651510
[TBL] [Abstract][Full Text] [Related]
56. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
57. [Impact of low-grade viremia on the risk of virological failure in patients with HIV-1 infection on antiretroviral therapy].
Viceconte R; Cisneros V; Sánchez Thomas D; Spacapan F; Fernández Ventura ML; Petriglieri C; Lopardo G
Rev Chilena Infectol; 2020 Nov; 37(5):550-554. PubMed ID: 33399802
[TBL] [Abstract][Full Text] [Related]
58. Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy.
Gaifer Z; Boulassel MR
J Int Assoc Provid AIDS Care; 2020; 19():2325958220979817. PubMed ID: 33372823
[TBL] [Abstract][Full Text] [Related]
59. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
[TBL] [Abstract][Full Text] [Related]
60. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
Quiros-Roldan E; Raffetti E; Castelli F; Focà E; Castelnuovo F; Di Pietro M; Gagliardini R; Gori A; Saracino A; Fornabaio C; Sighinolfi L; Di Filippo E; Maggiolo F; Donato F
J Antimicrob Chemother; 2016 Dec; 71(12):3519-3527. PubMed ID: 27543658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
